MI-1061 TFA

• CAT Number: I044350
• CAS Number: 1410737-35-7
• Molecular Formula: C32H27Cl2F4N3O6
• Molecular Weight: 696.47
• Purity: ≥95%
• InChI: InChI=1S/C30H26Cl2FN3O4.C2HF3O2/c31-17-9-12-20-22(15-17)35-28(40)30(20)23(19-5-4-6-21(32)24(19)33)25(36-29(30)13-2-1-3-14-29)26(37)34-18-10-7-16(8-11-18)27(38)39;3-2(4,5)1(6)7/h4-12,15,23,25,36H,1-3,13-14H2,(H,34,37)(H,35,40)(H,38,39);(H,6,7)/t23-,25+,30+;/m0./s1
• InChIKey: YVEFTHDIYIEZGS-FLLZXHAKSA-N
• SMILES: C1CCC2(CC1)[C@@]3([C@H]([C@@H](N2)C(=O)NC4=CC=C(C=C4)C(=O)O)C5=C(C(=CC=C5)Cl)F)C6=C(C=C(C=C6)Cl)NC3=O.C(=O)(C(F)(F)F)O

MI-1061 TFA（Cat No.:I044350）is a small-molecule inhibitor designed to target the menin–MLL (mixed-lineage leukemia) protein–protein interaction, a critical driver in MLL-rearranged leukemias. By disrupting this interaction, MI-1061 reactivates the expression of tumor suppressor genes and impairs leukemogenic transcriptional programs. The trifluoroacetate (TFA) salt form improves its stability and solubility for in vitro and in vivo studies. Preclinical research shows that MI-1061 TFA effectively reduces leukemia cell proliferation and induces differentiation and apoptosis. It represents a promising therapeutic candidate for treating aggressive MLL-rearranged and other epigenetically dysregulated hematologic malignancies.